

Chemistry

The amides (table I) and thioamides (table II) were prepared using the synthetic methods outlined in scheme 2. Activation of acids I by formation of an acyloxyphosphonium salt [4–6] was more easily and efficiently carried out using BrCCl_3 (*Method B*) than CCl_4 (*Method A*). Synthesis of *N*-methylpyrrole-carboxamide **13** by *Method B* gave *N*-methylpyrrole-2-carboxylic anhydride **25** as a by-product in a 28% yield. Preliminary *N*-substitution of indole-2-carboxylic acid was necessary to afford the desired *N*-(4,6-dimethylpyridinyl)-1-methylindole-2-carboxamide **14**. Indeed, only the formation of pyrazino-diindole-dione **26** was observed, in a 48% yield, with indole-2-carboxylic acid.

Attempts were made to increase yields by activating furan-2-carboxylic acid through the formation of an anhydride with 1,2-benzisoxazol-3-yl-diphenylphosphate [7]. This anhydride reacted sluggishly in acetonitrile, giving a very low yield (10%), which was moderately increased (to 40%) when this solvent was replaced with *N*-methylpyrrolidine-2-one (*Method C*).

Cyanation of amide **5**, performed with NaCN in DMSO at 120°C, gave 5-cyanofuran-2-carboxamide **6** in a 32% yield (*Method D*).

Sulfur/oxygen exchange of amides was carried out with phosphorus pentasulfide. Among the different anhydrous solvents experimented (pyridine, 3-methylpyridine, dioxane, HMPA, 1,3-dimethylimidazolidin-2-one, 1,3-dimethyl-3,4,5,6-tetrahydro-2-(1*H*)-pyrimidinone) only pyridine [8] afforded satisfactory results. The best yields, at least with the studied *N*-(2-dimethylpyridinyl)arylcarboxamides, were obtained by addition of the reagent to the gently heated (100°C) solution of amide in pyridine, followed by 75 min reflux (115°C). Prolongation of the reaction

time resulted in the formation of increased gummy by-products. Yields ranged between 45 and 75%, except for bromo derivative **20** which gave only a 16% yield which was not increased when the reaction was carried out in the presence of NaHCO_3 [9] in refluxing pyridine or toluene. Attempts to improve the yield of **20** by recourse to Lawesson's reagent [10–14] in refluxing toluene or HMPA at 90–95°C failed and only thioamides **15–17** could be isolated in very moderate yields (10–20%).

Minor by-products IV, corresponding to metadi-thiophosphonic derivatives (liable to exert antiinflammatory activity), were isolated during purification of thioamides **15** and **21**. The structural assignment of these orange-yellow compounds (**23** and **24**, respectively) was ascertained by IR, ^1H , ^{31}P -NMR and MS techniques (table III). The marked deshielding of pyridinyl H^3 , H^5 and $\alpha,\gamma\text{-CH}_3$ (when compared to their values in 6-amino-2,4-lutidine) argued in favor of a quaternized structure, with the cationic pyridinium site being equilibrated by the anionic sulfide site in IV. Further structural evidence of a betaine [1,4,2]-diazaphospholo[1,5-*a*]pyridinium sulfide structure IV was obtained from X-ray study [15].


The characteristic B, C, D and G infrared bands [16] of the thioamidic system were observed in the studied arylthiocarboxamides **15–22**. The most salient feature of the ^1H -NMR spectra of amides and thioamides was the marked deshielding of the H^3 signal (compared to the H^5 signal) of the pyridine nucleus, induced by the paramagnetic effect of the (thio)carbonyl group: $\Delta\delta \sim 1.2$ ppm and ~ 1.85 ppm for amides and thioamides, respectively. In the thiobenzamide series, the N-H peak appeared as a discrete broad singlet, likely due to rapid quadrupole-induced relaxation. IR and NMR data of amides I and thioamides II are shown in tables IV and V.

Pharmacological study and discussion

Inhibition of peripheral edema

The newly synthesized amides and thioamides were experimented as potential antiinflammatory molecules by measuring the inhibition of carrageenin-induced rat-paw edema after oral administration of 0.8 mmol· kg^{-1} . All tested heteroarylcarboxamides exerted an anti-edematous effect; compounds **3–5**, **8**, **9**, **11**, **12** and **14** demonstrated the highest potency ($\geq 90\%$ inhibition).

The presence of an EW group at the *meta* position in the furan ring exerted a varied effect: a marked decrease with cyano and nitro groups (**6** and **7**) and a slight increase with a bromo atom (**5**). Practically the same level of activity was obtained by an ED group like methyl (**4**). Benzene ring fusion to the furan



Scheme 2. Synthetic methods for amides II and thioamides III.

Table I. Physicochemical data and anti-edematous effect of heteroarylcarboxamides 3–14.

II

No.	Het-Ar	Formula M_r	Method yield (%)	F°C (diisopr. ether)	Carragenin-induced rat-paw edema ^{a)} Inhibition % ^{b)} $m \pm S_m$
3		$C_{12}H_{12}N_2O_2$ 216.24	A: 60 B: 61 C: 40	99-100	90.2 ± 4.8
4		$C_{13}H_{14}N_2O_2$ 230.37	B: 28	100-101	94.7 ± 3.7
5		$C_{12}H_{11}BrN_2O_2$ 295.14	A: 55 B: 51	128-129	97.3 ± 5.9
6		$C_{13}H_{11}N_3O_2$ 241.36	D: 32	97	78.7 ± 4.3
7		$C_{12}H_{11}N_3O_4$ 261.24	B: 60	178-179	60.7 ± 10.4
8		$C_{16}H_{14}N_2O_2$ 266.30	B: 55	129-130	91.6 ± 4.1
9		$C_{17}H_{16}N_2O_3$ 296.33	B: 46	155-157	91.7 ± 5.8
10		$C_{12}H_{12}N_2SO$ 232.24	A: 62 B: 65	152-153	80.8 ± 5.6
11		$C_{12}H_{12}N_2SO$ 232.24	B: 47	129	100
12		$C_{16}H_{14}N_2SO$ 282.37	B: 64	131	97.9 ± 4.7
13		$C_{13}H_{15}N_3O$ 229.28	B: 28	131	50.2 ± 6.0
14		$C_{17}H_{17}N_3O$ 279.34	B: 42	117-118	94.8 ± 7.7

^{a)}Dose: 0.8 mmol·kg⁻¹ po; ^{b)}number of animals for each group = 5.

Table II. Physicochemical data and anti-edematous effect of arylthiocarboxamides **15–18** and heteroarylthiocarboxamides **19–22**.

III

No.	R	Formula M_r	Method yield (%)	m.p. solvent	Carragenin-induced rat-paw edema ^d Inhibition % ^e $m \pm S_m$
15 ^a		C ₁₄ H ₁₄ N ₂ S 242.35	E: 60 F: 19	115-116 b	22.3 ± 8.5
16 ^a		C ₁₄ H ₁₃ FN ₂ S 260.33	E: 47 F: 14	99 b	86.9 ± 5.7
17 ^a		C ₁₄ H ₁₃ ClN ₂ S 276.79	E: 73 F: 12	63-64 b	NI
18 ^a		C ₁₅ H ₁₃ N ₃ S 267.36	E: 45	137-138 b	60.8 ± 10.1
19		C ₁₂ H ₁₂ N ₂ OS 232.31	E: 55	95 b	74.4 ± 4.5
20		C ₁₂ H ₁₁ BrN ₂ OS 311.21	E: 16	93-94 b	20.4 ± 9.2
21		C ₁₂ H ₁₂ N ₂ S ₂ 248.37	E: 52	125 b	84.4 ± 5.9
22		C ₁₆ H ₁₄ N ₂ OS 282.37	E: 66	123 c	61.5 ± 7.5

^aAmides have been described previously [1]; ^bdiisopropyl ether; ^cEtOH; ^ddose: 0.8 mmol·kg⁻¹ po; ^eNI: no inhibition; number of animals for each group = 5.


moiety did not modify the inhibition percentage (**3** → **8**), but a marked increase of activity was observed in the thiophene and especially the pyrrole subseries as a result of such a structural modification (**10** → **12** and **13** → **14**).

Transformation into thioamides did not notably change the level of activity in compounds **16**, **18** and **21** (by comparison with the corresponding amides), but led more generally to a decrease in potency or

even a loss of ability to inhibit edema (compound **17**). Lastly, integration of the pharmacophore into bicyclic betaine derivatives **23** and **24** caused the same dramatic loss of activity (inhibition < 20%).

Although tentative correlations were made between different physicochemical parameters (basicity (pK_a), lipophilicity ($\log P$) and intrinsic volume (V_x)) and antiinflammatory activity ($I\%$), no satisfactory single correlation was obtained. Multiple correlation analysis

Table III. Physicochemical and spectral data for compounds 23 and 24.



Compound	method : yield % m.p. °C; solvent	IR(KBr) cm ⁻¹	¹ H-NMR (DMSO-d ₆) δ ppm	³¹ P-NMR (CDCl ₃) δ ppm (32.44 MHz)	MS
<p>23</p> <p>Ar = </p> <p>C₁₄H₁₃N₂PS₂ 304.36</p>	E : 10 255 dec.; CH ₂ Cl ₂	1620 (νC=N) 720 (νP=S)	2.60 (s, 3H, 7-CH ₃); 3.38 (s, 3H, 5-CH ₃); 7.17 (s, 1H, H ⁶); 7.52 (s, 1H, H ⁸); 7.55-7.65 (m, 3 arom. H); 8.60-8.63 (m, 2 arom. H).	109.11 s	304 (11, M ⁺) 240 (100, M ⁺ -2S) 106 (77, C ₇ H ₈ N ⁺)
<p>24</p> <p>Ar = </p> <p>C₁₂H₁₁N₂PS₃ 310.40</p>	E : 4 245 dec.; CH ₂ Cl ₂	1620 (νC=N) 710 (νP=S)	2.58 (s, 3H, 7-CH ₃); 3.34 (s, 3H, 5-CH ₃); 7.12 (s, 1H, H ⁶); 7.46 (s, 1H, H ⁸); 7.32 (dd, 1H, H ^{4'} , J _{H^{4'}H^{5'}=3.9 Hz, J_{H^{4'}H^{3'}=4.5 Hz); 7.83 (dd, 1H, H^{5'}, J_{H^{5'}H^{4'}=3.9Hz, J_{H^{5'}H^{3'}=1Hz); 8.55 (dd, 1H, H^{3'}, J_{H^{3'}H^{4'}=4.5Hz, J_{H^{3'}H^{5'}=1Hz).}}}}}}		310 (15, M ⁺) 246 (100, M ⁺ -2S) 106 (59, C ₇ H ₈ N ⁺)

of the data showed that pK_a had no significant influence on activity level. Finally, a satisfactory relationship taking into account $\log P$ and V_x was obtained for six compounds (3–5, 7, 11 and 13):

$$\log I = 3.5 + 0.23 \log P - 11.21 \frac{V_x}{100} \quad (r = 0.975)$$

This suggests that, at a constant volume, activity is increased by higher lipophilicity and *vice versa*. Additional in-depth results, including values for previously described molecules as well as technical details, will be presented in a forthcoming paper.

The ID₅₀ value of one of the most active compounds, 5-bromofuran-2-carboxamide 5, was determined by linear regression after oral administration of four different doses to rats. It was higher than that of 3-fluorobenzamide 2, 30.95 mg·kg⁻¹ (I% = 32.225 D + 122.657; lack of fit: $P = 0.001$, NS) and 12.1 mg·kg⁻¹ respectively, but slightly lower than that of 1 (35.2 mg·kg⁻¹).

Toxicity tests

The acute toxicity of amide 5 was determined by oral administration of increasing doses to rats. Its LD₅₀ value, calculated according to the method of Lichtfield and Wilcoxon [17], was markedly higher than that of 2, 1830 mg·kg⁻¹ (1407–2380) and 280 mg·kg⁻¹ (189–414), respectively. Thus, amide 5 exhibited a more satisfactory therapeutic index (LD₅₀/ID₅₀) than fluorobenzamide 2 or even benzamide 1 (59, 23 and 52, respectively).

As the therapeutic potential of NSAIDs in chronic inflammatory processes is often burdened by a harmful effect on gastrointestinal mucosa, the ulcerogenic effect of 1 was evaluated by the rat pylorus ligation technique [18]. Its ulceration index, calculated by the Lwoff method [19], after intraduodenal administration of 200 mg·kg⁻¹, was practically identical with that obtained in control rats: 61.5 and 63.2. This value should be compared with that (300) obtained with phenylbutazone after administration of 100 mg·kg⁻¹.

Table IV. Spectral data for heteroarylcarboxamides and 3-14.

Compound	IR (KBr) cm^{-1} ν_{NH} , ν_{CO} , δ_{NH} , $\omega_{\text{comb}} \text{NH/CN}$	$^1\text{H-NMR}$ (CDCl_3) δ ppm
3	3400; 1665; 1530; 1280.	2.34 (s, 3H, 4-CH ₃); 2.42 (s, 3H, 6-CH ₃); 6.55 (dd, 1H, H ⁴ , $J_{\text{H}^4\text{H}^3} = 3.5\text{Hz}$, $J_{\text{H}^4\text{H}^5} = 1.6\text{Hz}$); 6.76 (s, 1H, pyr. H ⁵); 7.25 (dd, 1H, H ³ , $J_{\text{H}^3\text{H}^4} = 3.5\text{Hz}$, $J_{\text{H}^3\text{H}^5} = 0.8\text{Hz}$); 7.50 (dd, 1H, H ⁵ , $J_{\text{H}^5\text{H}^4} = 1.6\text{Hz}$, $J_{\text{H}^5\text{H}^3} = 0.8\text{Hz}$); 7.99 (s, 1H, pyr. H ³); 8.74 (s, 1H, NH).
4	3400; 1675; 1550; 1275.	2.33 (s, 3H, pyr. 4-CH ₃); 2.43 (s, 3H, pyr. 6-CH ₃); 2.36 (s, 3H, 5-CH ₃); 6.15 (d, 1H, H ⁴ , $J_{\text{H}^4\text{H}^3} = 3.0\text{Hz}$); 6.75 (s, 1H, pyr. H ⁵); 7.15 (d, 1H, H ³ , $J_{\text{H}^3\text{H}^4} = 3.0\text{Hz}$); 7.99 (s, 1H, pyr. H ³); 8.63 (s, 1H, NH).
5	3410; 1690; 1530; 1280.	2.34 (s, 3H, 4-CH ₃); 2.44 (s, 3H, 6-CH ₃); 6.49 (d, 1H, H ⁴ , $J_{\text{H}^4\text{H}^3} = 3.0\text{Hz}$); 6.77 (s, 1H, pyr. H ⁵); 7.21 (d, 1H, H ³ , $J_{\text{H}^3\text{H}^4} = 3.0\text{Hz}$); 7.95 (s, 1H, pyr. H ³); 8.63 (s, 1H, NH).
6	3100; 2220 ($\nu_{\text{C}=\text{N}}$); 1685; 1550; 1285.	2.36 (s, 3H, 4-CH ₃); 2.45 (s, 3H, 6-CH ₃); 6.82 (s, 1H, pyr. H ⁵); 7.22 (d, 1H, H ⁴ , $J_{\text{H}^4\text{H}^3} = 3.7\text{Hz}$); 7.31 (d, 1H, H ³ , $J_{\text{H}^3\text{H}^4} = 3.7\text{Hz}$); 7.91 (s, 1H, pyr. H ³); 8.68 (s, 1H, NH).
7	3210; 1685; 1555; 1280.	2.36 (s, 3H, 4-CH ₃); 2.44 (s, 3H, 6-CH ₃); 6.82 (s, 1H, pyr. H ⁵); 7.41 (s, 2H, H ³ and H ⁴); 7.91 (s, 1H, pyr. H ³); 8.91 (s, 1H, NH).
8	3400; 1680; 1525; 1275.	2.36 (s, 3H, 4-CH ₃); 2.46 (s, 3H, 6-CH ₃); 6.79 (s, 1H, pyr. H ⁵); 7.22-7.73 (m, 5 arom. H); 8.04 (s, 1H, pyr. H ³); 8.97 (s, 1H, NH).
9	3400; 1675; 1535; 1280.	2.37 (s, 3H, 4-CH ₃); 2.48 (s, 3H, 6-CH ₃); 4.03 (s, 3H, OCH ₃); 6.80 (s, 1H, pyr. H ⁵); 6.92 (dd, 1H, H ⁵ , $J_{\text{H}^5\text{H}^4} = 6.0\text{Hz}$, $J_{\text{H}^5\text{H}^6} = 3.0\text{Hz}$); 7.24 (d, 1H, H ⁴ , $J_{\text{H}^4\text{H}^5} = 6.0\text{Hz}$); 7.26 (d, 1H, H ⁶ , $J_{\text{H}^6\text{H}^5} = 3.0\text{Hz}$); 7.61 (s, 1H, H ³); 8.06 (s, 1H, pyr. H ³); 9.15 (s, 1H, NH).
10	3400; 1655; 1555; 1275.	2.33 (s, 6H, 4-CH ₃ and 6-CH ₃); 6.73 (s, 1H, pyr. H ⁵); 7.06 (dd, 1H, H ⁴ , $J_{\text{H}^4\text{H}^3} = 3.5\text{Hz}$, $J_{\text{H}^4\text{H}^5} = 4.9\text{Hz}$); 7.52 (dd, 1H, H ⁵ , $J_{\text{H}^5\text{H}^4} = 4.9\text{Hz}$, $J_{\text{H}^5\text{H}^3} = 0.92\text{Hz}$); 7.64 (dd, 1H, H ³ , $J_{\text{H}^3\text{H}^4} = 3.5\text{Hz}$, $J_{\text{H}^3\text{H}^5} = 0.92\text{Hz}$); 7.99 (s, 1H, pyr. H ³); 9.17 (s, 1H, NH).
11	3240; 1660; 1560; 1270.	2.35 (s, 3H, 4-CH ₃); 2.38 (s, 3H, 6-CH ₃); 6.75 (s, 1H, pyr. H ⁵); 7.39 (d, 1H, H ⁴ , $J_{\text{H}^4\text{H}^5} = 3.0\text{Hz}$); 7.54 (d, 1H, H ⁵ , $J_{\text{H}^5\text{H}^4} = 3.0\text{Hz}$); 8.02 (s, 2H, H ² and pyr. H ³); 8.69 (s, 1H, NH).
12	3415; 1675; 1540; 1280.	2.36 (s, 3H, 4-CH ₃); 2.44 (s, 3H, 6-CH ₃); 6.79 (s, 1H, pyr. H ⁵); 7.40-7.92 (m, 4 arom. H); 7.94 (s, 1H, H ³); 8.02 (s, 1H, pyr. H ³); 8.72 (s, 1H, NH).
13	3230; 1660; 1545; 1260.	2.33 (s, 3H, 4-CH ₃); 2.41 (s, 3H, 6-CH ₃); 3.99 (s, 3H, NCH ₃); 6.71 (s, 1H, pyr. H ⁵); 6.13 (dd, 1H, H ⁴ , $J_{\text{H}^4\text{H}^3} = 3.9\text{Hz}$, $J_{\text{H}^4\text{H}^5} = 2.8\text{Hz}$); 6.79 (dd, 1H, H ⁵ , $J_{\text{H}^5\text{H}^4} = 2.8\text{Hz}$, $J_{\text{H}^5\text{H}^3} = 1.7\text{Hz}$); 6.82 (dd, 1H, H ³ , $J_{\text{H}^3\text{H}^4} = 3.9\text{Hz}$, $J_{\text{H}^3\text{H}^5} = 1.7\text{Hz}$); 7.93 (s, 1H, pyr. H ³); 8.41 (s, 1H, NH).
14	3420; 1665; 1520; 1260.	2.35 (s, 3H, 4-CH ₃); 2.43 (s, 3H, 6-CH ₃); 4.10 (s, 3H, NCH ₃); 6.76 (s, 1H, pyr. H ⁵); 7.11-7.40 (m, 4 arom. H); 7.67 (s, 1H, H ³); 7.99 (s, 1H, pyr. H ³); 8.64 (s, 1H, NH).

Table V. Spectral data for arylthiocarboxamides and heteroarylthiocarboxamides 15–22.

Compound	IR(KBr) cm^{-1} Bands B, C, D, and G ^a)	$^1\text{H-NMR}$ (CDCl_3) δ ppm
15	1530, 1330, 1025, 780	2.40 (s, 3H, 4-CH ₃); 2.44 (s, 3H, 6-CH ₃); 6.87 (s, 1H, pyr. H ⁵); 7.45 (m, 3H, H ³ , H ⁴ and H ⁵); 7.85 (m, 2H, H ² and H ⁶) 8.80 (s, 1H, pyr. H ³); 10.0-10.5 (bs, 1H, NH).
16	1530, 1330, 1160, 780	2.39 (s, 3H, 4-CH ₃); 2.41 (s, 3H, 6-CH ₃); 6.86 (s, 1H, pyr. H ⁵); 7.13-7.67 (m, 4 arom. H); 8.60 (s, 1H, pyr. H ³); 10.0-10.5 (bs, 1H, NH).
17	1530, 1340, 1200, 710	2.40 (s, 3H, 4-CH ₃); 2.46 (s, 3H, 6-CH ₃); 6.87 (s, 1H, pyr. H ⁵); 7.23-7.87 (m, 4 arom. H); 8.62 (s, 1H, pyr. H ³); 10.0-10.5 (bs, 1H, NH).
18	1595, 1320, 1140, 720	2.41 (s, 3H, 4-CH ₃); 2.46 (s, 3H, 6-CH ₃); 6.88 (s, 1H, pyr. H ⁵); 7.30-7.48 (m, 4 arom. H); 8.27 (s, 1H, pyr. H ³); 10.0-10.5 (bs, 1H, NH).
19	1530, 1345, 1040, 760	2.38 (s, 3H, 4-CH ₃); 2.48 (s, 3H, 6-CH ₃); 6.52 (dd, 1H, H ⁴ , $J_{\text{H}^4\text{H}^3} = 3.6$ Hz, $J_{\text{H}^4\text{H}^5} = 1.8$ Hz); 6.86 (s, 1H, pyr. H ⁵); 7.46 (dd, 1H, H ³ , $J_{\text{H}^3\text{H}^4} = 3.6$ Hz, $J_{\text{H}^3\text{H}^5} = 0.7$ Hz); 7.51 (dd, 1H, H ⁵ , $J_{\text{H}^5\text{H}^4} = 1.8$ Hz, $J_{\text{H}^5\text{H}^3} = 0.7$ Hz); 8.81 (s, 1H, pyr. H ³); 10.01 (s, 1H, NH).
20	1560, 1360, 1020, 800	2.38 (s, 3H, 4-CH ₃); 2.47 (s, 3H, 6-CH ₃); 6.48 (d, 1H, H ⁴ , $J_{\text{H}^4\text{H}^3} = 3.6$ Hz); 6.87 (s, 1H, pyr. H ⁵); 7.50 (d, 1H, H ³ , $J_{\text{H}^3\text{H}^4} = 3.6$ Hz); 8.76 (s, 1H, pyr. H ³); 9.90 (s, 1H, NH).
21	1560, 1330, 1050, 715	2.38 (s, 3H, 4-CH ₃); 2.41 (s, 3H, 6-CH ₃); 6.81 (s, 1H, pyr. H ⁵); 7.06 (dd, 1H, H ⁴ , $J_{\text{H}^4\text{H}^3} = 4.5$ Hz, $J_{\text{H}^4\text{H}^5} = 3.5$ Hz); 7.50 (dd, 1H, H ³ , $J_{\text{H}^3\text{H}^4} = 4.5$ Hz, $J_{\text{H}^3\text{H}^5} = 1$ Hz); 7.62 (dd, 1H, H ⁵ , $J_{\text{H}^5\text{H}^4} = 3.0$ Hz, $J_{\text{H}^5\text{H}^3} = 1.0$ Hz); 8.36 (s, 1H, pyr. H ³); 10.77 (s, 1H, NH).
22	1530, 1350, 1120, 750	2.38 (s, 3H, 4-CH ₃); 2.49 (s, 3H, 6-CH ₃); 6.87 (s, 1H, pyr. H ⁵); 7.35-7.51 (m, 5 arom. H); 8.88 (s, 1H, pyr. H ³); 10.25 (s, 1H, NH).

^aSee ref [15].

Thus, these non-carboxylic NSAIDs could be particularly attractive for the development of new, safer antiinflammatory agents. These promising preliminary results justify further toxicity studies, which will be reported in a future manuscript by the same authors.

Inhibition of experimental brain edema

Among antiinflammatory drugs, only glucocorticoids are effective in the treatment of brain edema, although their therapeutic usefulness is limited by frequent and marked side effects. Two amides, **3** and **5**, were selected to evaluate inhibition of brain edema because of their high activity in peripheral edema. The assay was carried out using a rat PLA₂-induced brain edema

model [20]. As eicosanoid production has been clearly implicated in the development of experimental brain edema [21, 22], the decrease in edema was determined by measuring the PGE₂ concentration in drug-treated and untreated lesioned rats after IP administration of **3**, **5** and dexamethasone.

The results (table VI) show that the three non-steroidal compounds had a marked anti-edematous activity on experimental brain edema, which was higher than that observed with dexamethasone. It was previously observed [1] that benzamide **1** could reduce eicosanoid production despite its lack of direct inhibitory activity on cyclooxygenase, 5-lipoxygenase and phospholipase A₂. On the basis of these results, it is feasible to assume that new structurally related

heteroarylcarboxamides act by a similar mechanism, which is now under investigation. Recent experiments, especially those carried out with compound **5**, suggest that these new heteroarylcarboxamides perturb PKC activity (Lang *et al*, submitted for publication). Their mechanism of action would be partially related to an inhibitory effect on proteins located upstream from phospholipase A₂ on the pathway leading to activation of this enzyme by phosphorylation [23].

In conclusion, we have described the synthesis of some novel *N*-(4,6-dimethylpyridin-2-yl)heteroarylcarboxamides and a number of these possessed promising *in vivo* antiinflammatory activity. Furthermore two representative edema inhibitors, **3** and **5**, demonstrated good activity in brain edema. Confirmation of the original mechanism of action of these lead structures and their improved safety profile, when compared with standard antiinflammatory agents, is now under study and will be published in due course.

Experimental protocols

Chemistry

Melting points were determined on a Tottoli-Büchi apparatus, without correction. The structures of the described products were confirmed by IR, ¹H-NMR and microanalytical data. IR spectra were run with KBr pellets on a Beckman IR 4230 infrared spectrophotometer. ¹H-NMR spectra were recorded on a Bruker AC 250 spectrometer (250 MHz), CDCl₃ as solvent; chemical shifts (δ) are reported in parts per million (ppm) downfield from tetramethylsilane (Me₄Si, 0.00 ppm) as the internal standard and coupling constants in hertz. The ³¹P-NMR spectrum of **23** was recorded on a Jeol JNM-FX 200 spectrometer (32.44 MHz), CDCl₃ as solvent; chemical shifts (δ) are reported in ppm from phosphoric acid (H₃PO₄, 0.00 ppm) as an external standard. Structural assignment of compounds **23–26** was completed by mass spectroscopy, using a Hewlett-Packard HP 5989 A spectrometer operating in electron ionization (EI) mode (70 eV). Samples were introduced by a direct inlet probe at the minimum temperature providing adequate vapor pressure; source temperature: 220°C Microanalyses were performed on a Perkin-Elmer CHN 240 apparatus. Analyses indicated by the symbols of the elements were within ± 0.40%

of theoretical values. TLC was performed on precoated silica gel aluminium plates (0.2 mm, GF254, E Merck). Spots were located by UV detection.

Sodium sulfate was always used as the drying agent. Products were routinely purified by short columns of silica gel (silica gel 60, 70-230 mesh, E Merck), with CH₂Cl₂ as an eluent. Commercially available (Aldrich, Janssen) acids were used, except for 5-methylfuran-2-carboxylic acid, which was prepared by KMnO₄ or Ag₂O oxidation of the corresponding aldehyde in 26 and 35% yields respectively; mp = 109–110°C (diisopropyl ether), lit [24]: 119°C. IR (KBr) cm⁻¹: 3180–2520 (νOH), 1680 (νC=O), 905 (δOH). ¹H-NMR (CDCl₃) δ ppm: 2.35 (s, 3H, CH₃); 6.30 (d, 1H, *J* = 3.3 Hz, H⁴), 7.12 (d, 1H, H³); 12.84 (s, 1H, COOH).

The following experimental procedures are illustrative of the general ones used to afford amides and thioamides.

Method A. *N*-(4,6-Dimethylpyridin-2-yl)furan-2-carboxamide 3
A mixture of triphenylphosphine (7 g, 26.77 mmol) and tetrachloromethane (5.17 ml, 53.54 mmol) in THF (70 ml) was refluxed for 30 min and cooled at 5°C, after which furan-2-carboxylic acid (3 g, 26.77 mmol) was added. The mixture was stirred for 10 min before 2-amino-4,6-dimethylpyridine (6.54 g, 53.54 mmol) was added. The solution was again refluxed for 1 h and cooled to room temperature. The precipitate was removed by filtration, and filtrate concentrated by evaporation under reduced pressure. The residue, purified by column chromatography, gave 3.46 g of pure product. Yield: 60%; mp: 98–100°C (diisopropyl ether). IR (KBr) cm⁻¹: 3340 (νNH); 1675 (νC=O); 1570 (δNH); 1280 (combined NH/CN). ¹H-NMR (CDCl₃) δ ppm: 2.34 (s, 3H, 4-CH₃); 2.42 (s, 3H, 6-CH₃); 6.55 (dd, 1H, H⁴, *J*_{H⁴H³} = 3.5 Hz, *J*_{H⁴H⁵} = 1.6 Hz); 6.76 (s, 1H, pyr H⁵); 7.25 (dd, 1H, H³, *J*_{H³H⁴} = 1.6 Hz, *J*_{H³H⁵} = 0.8 Hz); 7.50 (dd, 1H, H⁵, *J*_{H⁵H⁴} = 1.6 Hz, *J*_{H⁵H³} = 0.8 Hz); 7.99 (s, 1H, pyr H³); 8.74 (s, 1H, NH). Anal C₁₂H₁₂N₂O₂ (C, H, N).


Method B. *N*-(4,6-Dimethylpyridin-2-yl)thiophene-2-carboxamide 10
A mixture of triphenylphosphine (8.19 g, 31.21 mmol), thiophene-2-carboxylic acid (4.00 g, 31.21 mmol), bromotrichloromethane (6.15 ml, 62.42 mmol) and 2-amino-4,6-dimethylpyridine (7.62 g, 31.21 mmol) was refluxed under stirring for 34 h and then cooled to room temperature. The mixture was filtered under vacuum, and the filtrate was concentrated under reduced pressure to give a brown oil. After purification by column chromatography, this residue gave 4.68 g of pure carboxamide **10**. Yield: 65%; mp: 152–153°C (diisopropyl ether). IR (KBr) cm⁻¹: 3200 (νNH); 1660 (νC=O); 1560 (δNH); 1275 (combined NH/CN). ¹H-NMR (CDCl₃) δ ppm:

Table VI. Influence of drug treatment on the brain PGE₂ tissue concentration.

Compound	IP dose (μmol·kg ⁻¹)	PGE ₂ concentration (pg·mg ⁻¹ of proteins)	Number of animals
1	12.5	79.2 ± 14.3	14
3	12.5	42.9 ± 3.0	13
5	12.5	35.7 ± 2.3	10
Dexamethasone	26	89.8 ± 11.9	11
Lesioned rats		293.9 ± 12.2	11
Control rats		21.1 ± 1.8	16


2.33 (s, 6H, 4-CH₃ and 6-CH₃); 6.73 (s, 1H, pyr H⁵); 7.06 (dd, 1H, H⁴, $J_{\text{H}^3\text{H}^4} = 4.9$ Hz; $J_{\text{H}^3\text{H}^5} = 3.5$ Hz); 7.53 (dd, 1H, H⁵, $J_{\text{H}^3\text{H}^4} = 4.9$ Hz, $J_{\text{H}^5\text{H}^3} = 0.92$ Hz); 7.64 (s, 1H, H³, $J_{\text{H}^3\text{H}^4} = 3.5$ Hz, $J_{\text{H}^3\text{H}^5} = 0.92$ Hz); 7.99 (s, 1H, pyr H³); 9.17 (s, 1H, NH). Anal C₁₂H₁₂N₂SO (C, H, N).

N-(4,6-Dimethylpyrrole-2-carboxylic anhydride **25** was simultaneously obtained when the amine was condensed with the corresponding acid by *Method B*.



Yield: 28%; mp: 70°C (diisopropyl ether). IR (KBr) cm⁻¹: 1760 (ν_{as}C=O); 1700 (νC=O); 1035 (νC-O-C). ¹H-NMR (CDCl₃) δ ppm: 3.97 (s, 6H, 2NCH₃); 6.16 (dd, 2H, H⁴ and H⁴, $J_{\text{H}^3\text{H}^4} = 4.1$ Hz, $J_{\text{H}^4\text{H}^5} = 2.5$ Hz); 6.92 (dd, 2H, H⁵ and H⁵, $J_{\text{H}^3\text{H}^4} = 2.5$ Hz, $J_{\text{H}^5\text{H}^3} = 1.9$ Hz); 7.09 (dd, 2H, H³ and H³, $J_{\text{H}^3\text{H}^4} = 4.1$ Hz, $J_{\text{H}^3\text{H}^5} = 1.9$ Hz). MS: 232 (22, M⁺); 108 (100, C₆H₆NO⁺).

6*H*,13*H*-Pyrazino[1,2-*a*:4,5-*a'*]indole-6-13-dione **26** was the only product isolated when an attempt was made to condense 2-amino-4,6-dimethylpyridine with indole-2-carboxylic acid by *Method B*.



Yield: 48%; mp: 306–309°C (CH₂Cl₂). IR (KBr) cm⁻¹: 1695, 1680 (νC=O). ¹H-NMR (DMSO-*d*₆) δ ppm: 7.44–8.52 (m, 10H). MS: 286 (100, M⁺), 258 (12, M⁺ - CO), 143 (43, C₉H₅NO⁺), 115 (52, C₈H₅N⁺).

Method C. N-(4,6-Dimethylpyridin-2-yl)furan-2-carboxamide **3** Furan-2-carboxylic acid (0.56 g, 4.96 mmol) was dissolved in *N*-methylpyrrolidin-2-one (5 ml). TEA (0.8 ml, 4.96 mmol) and 1,2-benzisoxazol-3-yl diphenylphosphate (2 g, 4.96 mmol) were added. The solution was stirred for 2 h at room temperature and then poured into a 1% water solution of NaHCO₃ (30 ml). This mixture was extracted by dichloromethane (3 × 30 ml). The organic layer was dried and concentrated under vacuum. The residue, after purification by column chromatography, gave 0.43 g of pure product. Yield: 40%; mp 98–100°C (diisopropyl ether). IR, ¹H-NMR see *Method A*.

Method D. N-(4,6-Dimethylpyridin-2-yl)-5-cyanofuran-2-carboxamide **6**

N-(4,6-Dimethylpyridin-2-yl)-5-bromofuran-2-carboxamide **5** (6.63 g, 22.46 mmol) was dissolved in DMSO (30 ml). NaCN (1.13 g, 23 mmol) was added, and the mixture was then stirred at 120°C for 3 h. After cooling to room temperature, water (50 ml) was added, and the mixture was extracted with dichloromethane (3 × 80 ml). The organic layers were collected, dried and evaporated under vacuum. The residue was purified by column chromatography to give 1.74 g of pure product. Yield: 32%; mp: 97°C (diisopropyl ether). IR (KBr) cm⁻¹: 3100 (νNH); 2220 (νC≡N); 1685 (νC=O); 1550 (δNH); 1285 (combined NH/CN). ¹H-NMR (CDCl₃) δ ppm: 2.36 (s, 3H,

4-CH₃); 2.45 (s, 3H, 6-CH₃); 6.82 (s, 1H, pyr H⁵); 7.22 (d, 1H, H⁴, $J_{\text{H}^3\text{H}^4} = 3.7$ Hz); 7.31 (d, 1H, H³, $J_{\text{H}^3\text{H}^4} = 3.7$ Hz); 7.91 (s, 1H, pyr H³); 8.68 (s, 1H, NH). Anal C₁₃H₁₀N₃O₂ (C, H, N).

Method E. N-(4,6-Dimethylpyridin-2-yl)furan-2-thiocarboxamide **19**

N-(4,6-Dimethylpyridin-2-yl)furan-2-carboxamide (6.5 g, 30.1 mmol) was dissolved in anhydrous pyridine (60 ml), and the solution was then heated to 100–110°C. P₄S₁₀ (10.22 g, 23 mmol) was added, and the mixture was refluxed for 75 min. It was then poured into 300 ml of ice-water and stirred vigorously for 15–20 min. The precipitate was separated by filtration and dried. This crude product, purified by column chromatography, gave 3.85 g of pure yellow product. Yield: 55%; mp: 95°C (diisopropyl ether). IR (KBr) cm⁻¹: 1530 (ν_{as}NCS); 1345 (combined NC/CS); 1040 (ν_sNCS). ¹H-NMR (CDCl₃) δ ppm: 2.38 (s, 3H, 4-CH₃); 2.46 (s, 3H, 6-CH₃); 6.52 (dd, 1H, H⁴, $J_{\text{H}^3\text{H}^4} = 3.6$ Hz, $J_{\text{H}^4\text{H}^5} = 1.8$ Hz); 6.86 (s, 1H, pyr H⁵); 7.46 (dd, 1H, H³, $J_{\text{H}^3\text{H}^4} = 3.6$ Hz, $J_{\text{H}^3\text{H}^5} = 0.7$ Hz); 7.51 (dd, 1H, H⁵, $J_{\text{H}^5\text{H}^4} = 1.8$ Hz, $J_{\text{H}^5\text{H}^3} = 0.7$ Hz); 8.81 (s, 1H, pyr H³); 10.01 (s, 1H, NH). Anal C₁₂H₁₂N₂OS (C, H, N).

Method F. N-(4,6-Dimethylpyridin-2-yl)benzenethiocarboxamide **15**

N-(4,6-Dimethylpyridin-2-yl)benzenecarboxamide (1 g, 4.42 mmol) was dissolved in HMPA (10 ml) and heated to 90–95°C. Lawesson's reagent (3.6 g, 8.84 mmol) was added, and the mixture was stirred for 10 h. The dark solution obtained was poured into 100 ml of cold water (0–5°C), and the mixture was then stirred for 20 min. The precipitate obtained was washed with water (3 × 100 ml), dried and purified by column chromatography, affording 0.2 g of pure product. Yield: 19%; mp 115–116°C (diisopropyl ether). IR (KBr) cm⁻¹: 1530 (ν_{as}NCS); 1330 (combined NC/CS); 1025 (ν_sNCS). ¹H-NMR (CDCl₃) δ ppm: 2.40 (s, 3H, 4-CH₃); 2.44 (s, 3H, 6-CH₃); 6.87 (s, 1H, pyr H⁵); 7.45 (m, 3H, H³, H⁴ and H⁵); 7.85 (m, 2H, H² and H⁶); 8.80 (s, 1H, pyr H³); NH: not observed. Anal C₁₄H₁₄N₂S (C, H, N).

Pharmacology

These studies were carried out on adult male Wistar CF rats weighing 180–220 g.

Carrageenin-induced rat-paw edema

The inhibitory activity of the studied molecules on carrageenin-induced rat-paw edema was determined according to the method of Winter *et al* [25], with slight modification. The drugs were orally administered 1 h before injection of 0.05 ml of a 1% suspension of carrageenin in saline into the subcutaneous tissues of one hind paw. The other hind paw was injected identically with 0.05 ml of a saline solution. Since the hydration state of animals can modify the intensity of swelling, rats were fasted 24 h before the experiment, and water (1.5 ml/100 g body weight) was orally administered twice (20 h and 4 h) before injections. Volumes of both hind paws of control and treated animals were measured with a plethysmograph 3 h after injection. Rats were kept in the same experimental conditions.

The inhibition percentage of the inflammatory reaction was determined for each animal by comparison with controls and calculated by the formula:

$$I\% = \left(1 - \frac{dt}{dc}\right) \times 100$$

where dt is the difference in paw volume in the drug-treated group and dc the difference in paw volume in the control group. Data are expressed as mean \pm SE.

Ulcerogenic activity

Rats were divided into groups of 10 animals and fasted for 24 h prior to drug administration, receiving water *ad libitum*. After pylorus ligation [18], compound 1 was administered intraduodenally to an experimental group at a dose of 200 mg/kg in the form of an aqueous suspension in gum acacia. One group was used as a control, and another received the standard drug phenylbutazone at a dose of 100 mg/kg. The animals were sacrificed 18 h after drug or gum acacia treatment. Their stomachs were removed, opened up along the greater curvature and examined for the presence of gastric ulcers. An index based on the following formula was calculated using the Lwoff method [19]:

$$\frac{\text{sum of scores} \times \text{percentage of animals with ulcers}}{\text{number of animals}}$$

Experimental brain edema

Studies of PGE₂ brain levels were carried out as follows. Rats were housed in the animal room under artificial lighting between 6 am and 9 pm, with an ambient temperature of 21–23°C. They received food and water *ad libitum*. Injections and samplings were performed under ketamine anaesthesia (200 mg/kg intramuscularly) after placement of the animals in a stereotaxic apparatus. Our experiments used a brain edema model, developed in our laboratory, which was obtained by a phospholipase A₂ (PLA₂ from *Naja naja* venom, Sigma, USA) intracerebral injection. After perforation of the skull in the right hemisphere, 4 IU of PLA₂ (dissolved in 100 mM Tris, 1 mM CaCl₂, pH 7.4) was injected into the frontal cortex brain structure, according to the following stereotaxic coordinates: A = + 2 mm, L = + 2 mm, H = - 3.5 mm, with respect to the bregma [26]. Animals were kept for 24 h after the operation. Four groups of animals were used: control rats, lesioned rats, rats treated with dexamethasone (26 μ mol/kg intraperitoneally) (Merck, Sharp & Dohme Laboratories, France) and rats treated with the studied compounds (12.5 μ mol/kg intraperitoneally). Drugs were injected only once (5 h before PLA₂ injection).

Brain sampling was done under liquid nitrogen, 24 h after PLA₂ injection. Brain tissue (50–100 mg) was homogenized with 3 ml of acetone and centrifuged at 1200 g (20 min at 4°C). After evaporation of supernatants under nitrogen, residues were resuspended in phosphate-buffered saline (0.1 mol/l, pH 7.4, containing 1 mg/ml of gelatine). Aliquots were used for determination of PGE₂ by radioimmunoassay. It was verified that the drugs used did not interfere with the radioimmunoassay.

Acknowledgments

The authors wish to thank MR Nourrisson for skillful help in experimental work and JC Bollinger (College of Sciences, Limoges, France) for expert assistance in performing the QSAR assay.

References

- Robert-Piessard S, Le Baut G, Courant J *et al* (1990) *Eur J Med Chem* 25, 9–19
- Robert JM, Robert-Piessard S, Duflos M *et al* (1994) *Eur J Med Chem* 29, 841–854
- Floersheim P, Pombo-Villar E, Shapiro G (1992) *Chimia* 46, 323–334
- Downie IM, Lee JB, Matough MES (1968) *Chem Commun* 1350–1351
- Lee JB (1966) *J Am Chem Soc* 88, 3439–3440
- Barstow LE, Hruby VJ (1971) *J Org Chem* 36, 1305–1306
- Ueda M, Oikawa H (1985) *J Org Chem* 50, 760–763
- Farina C, Pinza M, Gamba A, Pifferi G (1979) *Eur J Med Chem* 14, 27–31
- Lilje KC (1987) *Eur Pat EP* 212 569, 04-03-1987, *Chem Abstr* (1987) 107, P23368t
- Cherkasov RA, Kutyrev GA, Pudovik AN (1985) *Tetrahedron* 41, 2567–2624
- Pedersen BS, Lawesson SO (1977) *Bull Soc Chim Belg* 86, 693–697
- Perregard J, Thomeson I, Lawesson SO (1977) *Bull Soc Chim Belg* 86, 321–328
- Scheibye S, Pedersen BS, Lawesson SO (1978) *Bull Soc Chim Belg* 87, 229–238
- Pedersen BS, Scheibye S, Clausen K, Lawesson SO (1978) *Bull Soc Chim Belg* 87, 293–297
- Rodier N, Cense JM, Robert JM, Robert-Piessard S, Courant J, Le Baut G (1994) *Acta Cryst C* 50, 810–813
- Jensen KA, Nielsen PH (1966) *Acta Chem Scand* 20, 597–629
- Lichtfield JT, Wilcoxon FA (1949) *J Pharmacol Exp Ther* 95, 99–113
- Shay H, Komarov SA, Fels SS, Meranze D, Cwensstein M, Siplet H (1945) *Gastroenterology* 5, 43–61
- Lwoff JM (1971) *J Pharmacol* 2, 81–83
- Robert B, Robert JMH, Khettab E, Grmoud N, Petit JY, Welin L (1992) *Pharmacol Toxicol* 70, 67–69
- Dempsey RJ, Roy MW, Meyer K, Cowen DE, Tai HH (1986) *J Neurosurg* 66, 118–124
- Ambrus JL, Halpern J, Baerwald H, Johnson R (1985) *Lancet* 2, 148–149
- Lin LL, Wartmann M, Lin AY, Knopf JL, Peth A, Davis TJ (1993) *Cell* 72, 269–278
- Korte F, Heinz R, Scharf D (1961) *Chem Ber* 94, 825–831
- Winter CA, Risley EA, Nuss CW (1962) *Proc Soc Exp Biol Med* 11, 544
- König JFR, Klippel RA (1963) *The Rat Brain A Stereotaxic Atlas of the Forebrain and Lower Parts of the Brain Stem*, Williams and Wilkin, Baltimore, USA